A ready-to-formulate lipopeptide premix for premium anti-aging and wrinkle-appearance cosmetic development. The liquid combines Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7 (Pal-GQPR) at a merchant-confirmed total peptide content of ppm. Instead of asking formulators to weigh microgram-level peptide powders, the premix format provides a practical route for controlled dosing into serums, eye products and emulsions. The exact carrier, preservative system and individual peptide ratio should be confirmed from the current product specification before production scale-up.
- 200 ppm total Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 in a premixed liquid format.
- Designed for fine-line, wrinkle-appearance, firmness and skin-texture product concepts.
- Premix format simplifies dosing compared with handling individual high-purity peptide powders.
- Suitable for R&D, small-pack evaluation and commercial bulk sourcing.
Product Specifications / Key Facts
|
Property |
Product Information |
|
Product Name |
Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Peptide Blend |
|
Commercial Form |
Premix liquid / stock solution |
|
Total Peptide Content |
200 ppm total peptides (0.020% w/w nominal basis) |
|
Active 1 |
Palmitoyl Tripeptide-1 (Pal-GHK) |
|
Active 1 CAS / Formula |
147732-56-7 / C30H54N6O5 [R3] |
|
Active 2 |
Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
|
Active 2 CAS / Formula |
221227-05-0 / C34H62N8O7 [R4] |
Key Benefits
Supports fine-line and wrinkle-appearance formulas — The Pal-GHK / Pal-GQPR combination is widely used in premium age-support peptide systems. Branded and multi-component finished-formula studies support appearance-focused anti-aging positioning. [R2,R5]
Supports firmer-looking skin concepts — Lipopeptide systems built around these two actives are commonly positioned for extracellular-matrix and firmness-focused cosmetic development.
Adds a premium dual-peptide story — Using two complementary palmitoylated peptides gives formulators a clear advanced-peptide positioning beyond a single-peptide active.
Simplifies micro-dose handling — At 200 ppm total peptide, the premix lets formulators dose a liquid ingredient at practical percentages rather than weigh extremely small amounts of individual peptide powders.
Supports repeatable active-loading calculations — A defined total-peptide range allows the formulator to estimate the nominal peptide ppm delivered to the finished product and then verify the batch against the current supplier specification.
Understanding the 200 ppm Peptide Basis
The 200 ppm specification refers to the total amount of Palmitoyl Tripeptide-1 plus Palmitoyl Tetrapeptide-7 in the supplied premix. It is not a 13–20% peptide concentrate: 200 ppm equals approximately 0.020% total peptide in the raw liquid. The rest of the product is the carrier / premix system, which must be confirmed from the current composition document.
|
Premix in Finished Formula |
Nominal Total Peptide Delivered |
|
1% |
2.0 ppm |
|
3% |
6.0 ppm |
|
5% |
10.0 ppm |
|
8% |
16.0 ppm |
Typical Applications
- Anti-aging facial serums
- Eye creams and eye serums
- Firming moisturizers and gel-creams
- Neck and décolletage age-support care
- Premium multi-peptide formulations
Quick Formulation Guide
|
Parameter |
Typical Formulation Guidance |
|
Use Level |
commonly recommended around 3%. [R2,R6–R9] |
|
Phase / Addition |
Comparable premix liquids are designed for aqueous-phase or cool-down addition rather than direct oil-phase use. [R2,R6–R8] |
|
Temperature |
Peptide premixes are commonly added during cool-down / low-temperature processing. Avoid unnecessary heat exposure[R6–R7] |
Why Source From Us
- Start with samples scale to bulk orders – one supplier from trial to production: Validate with lab samples, then scale to commercial volumes – same quality, same team. No re-qualification, no project delays.
- Formulation support that actually helps – not just a data sheet: We give you hands-on guidance on solubility, temperature, pH, and compatibility. A real formulation partner, not a catalog.
- Reliable supply chain – consistent quality, on-time delivery, batch after batch: Own manufacturing facilities plus long-term partnerships with audited upstream producers ensure batch-to-batch consistency. Full documentation with every shipment. No "sample passes, bulk fails"
- Export-ready documentation – compliance, customs, cleared：Complete technical documentation packages – COA, MSDS, TDS, stability data – batch-specific and regulatory-ready. We handle the paperwork so your compliance and procurement teams can focus on formulation
Recommended Ingredient Pairings
|
Recommended Ingredient |
Why It Pairs Well |
Product Concept |
Compatibility Note |
|
Adds barrier, tone and hydration support to a multi-pathway age-support formula. |
Dual-peptide + niacinamide serum |
Validate pH, carrier/preservative compatibility and long-term appearance. |
|
|
Adds barrier-lipid support to the wrinkle/firmness peptide story. |
Peptide barrier-repair cream |
Requires appropriate lipid/emulsion architecture; validate peptide stability. |
|
|
Adds hydration and slip to peptide serums. |
Hydrating peptide serum |
Check viscosity after the premix carrier and electrolytes are introduced. |
|
|
Supports conditioning and comfort in daily-use peptide formulas. |
Soothing firming serum |
Confirm final pH and preservation. |
|
|
Creates a premium multi-peptide anti-aging concept with a distinct cosmetic positioning route. |
Multi-peptide expression-line serum |
Validate each peptide and complete formula; do not promise automatic synergy. |
|
|
Adds antioxidant support in emulsions or complementary lipid-phase design. |
Peptide antioxidant cream |
Different phase requirements; antioxidant support does not replace peptide stability testing. |
Scientific & Commercial Evidence Snapshot
Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7 are the two lipopeptides associated with the Matrixyl® 3000 concept. Croda/Sederma has a long-established Matrixyl peptide brand and branded Matrixyl® 3000 is supplied as a liquid premix containing both peptides. [R1–R2] Human clinical evidence is often tied to branded trade formulations or multi-component finished products. A recent 12-week eye-cream study included both peptides alongside other actives and reported improvements in hydration, elasticity and collagen-density-related endpoints. [R5]
Research & References
[R1] Croda — Sederma Matrixyl brand history.
[R3] PubChem — Palmitoyl Tripeptide-1, CAS 147732-56-7, C30H54N6O5.
[R4] PubChem — Palmitoyl Tetrapeptide-7, CAS 221227-05-0, C34H62N8O7.
[R6] Essentials by Catalina — Matrixyl® 3000 technical product page.
Request a Quote
Tell us your required quantity, destination country, and any documentation needs. We usually reply within 1 business day.